Every material Form 8-K IMMUNIC, INC. has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Immunic, Inc. disclosed that it is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar on November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET. The company furnished a presentation for the event as Exhibit 99.1. The filing contains no financial results, guidance, or transaction terms.
PMS R&D Day webinar held via video conference on Thursday, November 5, 2026, 12:30 p.m. to 2:00 p.m. ET
Presentation dated November 5, 2026, furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
Forward-looking statements cite the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 trial in progressive multiple sclerosis
Immunic director Dr. Duane Nash resigned from the Board of Directors on September 10, 2026. The company said the resignation was not due to any disagreement over its operations, policies, or practices, and the board reduced its size from ten members to nine.
Dr. Duane Nash resigned as a director on September 10, 2026.
The filing states no disagreement with the company on operations, policies, or practices.
Board size reduced from ten members to nine members.
Immunic, Inc. is hosting a Relapsing Multiple Sclerosis (RMS) Research and Development Day webinar on September 9, 2026, from 11:00 a.m. to 12:30 p.m. ET, and has filed a presentation for the event as Exhibit 99.1. The filing contains no financial results, guidance, or new clinical data beyond the presentation itself, so the event is routine for shareholders.
RMS R&D Day webinar held September 9, 2026, 11:00 a.m. to 12:30 p.m. ET by video conference
Company presentation dated September 9, 2026 furnished as Exhibit 99.1
Filing is furnished under Regulation FD and not deemed filed under Section 18 of the Exchange Act
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IMMUNIC, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →